-
1.发明申请Use of the Combinatorial Diversity of T-Lymphocyte Repertoire as a Prognostic Marker of Cancer 审中-公开T淋巴细胞谱系组合多样性的使用作为癌症的预后标记公开(公告)号：US20120309013A1
公开(公告)日：2012-12-06
申请号：US13514842
申请日：2010-12-09
申请人： Christophe Caux , Jean-François Mouret , Christine Menetrier-Caux , Nicolas Pasqual , Thomas Bachelot , Manuarii Manuel , Jean-Yves Blay
发明人： Christophe Caux , Jean-François Mouret , Christine Menetrier-Caux , Nicolas Pasqual , Thomas Bachelot , Manuarii Manuel , Jean-Yves Blay
IPC分类号： G01N21/76
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/16
摘要： The present invention relates to a method making it possible to identify the patients, from among those affected by a given solid cancer, that have increased risk of premature death. Said method is based on the ex vivo analysis of the lymphocytic diversity of the patients on the basis of a biological sample containing lymphocytes. In fact, low lymphocytic diversity is related to a poor prognosis. Specifically, it is possible to set a diversity threshold, depending on the analysis technology used and the cancer affecting the patient, beyond which the life expectancy of the patient is significantly less than that, in general, of the patients affected by the same disease.
摘要翻译： 本发明涉及一种使得可能鉴定出患有早期死亡风险增加的患者，从受到特定实体癌症影响的患者中。 所述方法基于在含有淋巴细胞的生物样品的基础上对患者的淋巴细胞多样性的离体分析。 事实上，低淋巴细胞多样性与预后不良有关。 具体地，可以根据所使用的分析技术和影响患者的癌症来设定多样性阈值，超过该阈值的患者的预期寿命明显低于一般受同一疾病影响的患者的预期寿命。
-
2.发明授权公开(公告)号：US07081526B2
公开(公告)日：2006-07-25
申请号：US10731811
申请日：2003-12-09
摘要： The invention relates to the use of morpholino-nucleosides of formula: in which R1 represents a nucleic base and R2 represents a group corresponding to one of the following formulae: —(CH2)n—NH2 —(CH2)n—SH —(CH2)n—COOH —(CH2)n—OH —(CH2)n—NH—R3 —(CH2)n—SR3 —(CH2)n—CO—R3 —(CH2)n—OR3 in which n is an interger ranging from 1 to 12 and R3 is a group derived from a label, from a protein, from an enzyme, from a fatty acid or from a peptide, as chain terminators in a process of DNA or RNA sequencing by the Sanger method, or for the labelling of DNA or RNA fragments.
摘要翻译： 本发明涉及下式的吗啉代核苷的用途：其中R 1表示核酸，R 2表示对应于下式之一的基团： ？in-line-formula description =“In-line Formulas”end =“lead”？> - （CH 2） n 2 - （CH 2） n -SH <？in-line-formula description =“In-line Formulas”end =“tail”？> <？in-line -formulae description =“In-line Formulas”end =“lead”？ - （CH 2） ）线性公式描述=“在线公式”end =“tail”？> <？in-line-formula description =“In-line Formulas”end = - （CH 2）n - -NH-R 3 - （CH 2） “in-line-formula description =”In-line Formulas“end =”tail“？> <？in-line-formula description =”In - （CH 2）n - （CH 2）n - （CH 2） - （CH 2） ＆lt; / SUB＆gt;＆lt; n＆lt; 3＆lt; 3＆lt; 3＆lt;＆lt;＆lt; in-line-formula description = 其中n为1至12的整数，R 3为来自标记的基团，来自蛋白质，酶，来自 脂肪酸或肽，作为通过Sanger方法进行DNA或RNA测序的方法中的链终止子，或用于标记DNA或RNA片段。
-
3.发明授权公开(公告)号：US07314928B2
公开(公告)日：2008-01-01
申请号：US11411505
申请日：2006-04-26
摘要： The invention relates to the use of morpholino-nucleosides of formula: in which R1 represents a nucleic base and R2 represents a group corresponding to one of the following formulae: —(CH2)n—NH2 —(CH2)n—SH —(CH2)n—COOH —(CH2)n—OH —(CH2)n—NH—R3 —(CH2)n—SR3 —(CH2)n—CO—R3 —(CH2)n—OR3 in which n is an interger ranging from 1 to 12 and R3 is a group derived from a label, from a protein, from an enzyme, from a fatty acid or from a peptide, as chain terminators in a process of DNA or RNA sequencing by the Sanger method, or for the labelling of DNA or RNA fragments.
摘要翻译： 本发明涉及下式的吗啉代核苷的用途：其中R 1表示核酸，R 2表示对应于下式之一的基团： ？in-line-formula description =“In-line Formulas”end =“lead”？> - （CH 2） n 2 - （CH 2） n -SH <？in-line-formula description =“In-line Formulas”end =“tail”？> <？in-line -formulae description =“In-line Formulas”end =“lead”？ - （CH 2） ）线性公式描述=“在线公式”end =“tail”？> <？in-line-formula description =“In-line Formulas”end = - （CH 2）n - -NH-R 3 - （CH 2） “in-line-formula description =”In-line Formulas“end =”tail“？> <？in-line-formula description =”In - （CH 2）n - （CH 2）n - （CH 2） - （CH 2） ＆lt; / SUB＆gt;＆lt; 3＆lt; 3＆lt; 3＆lt; =“在线公式”end =“tail”？>其中n是1至12的整数，R 3是从蛋白质衍生自标签的基团，来自酶 ，从脂肪酸或肽中作为链终止子，通过Sanger方法进行DNA或RNA测序，或用于标记DNA或RNA片段。
-
公开(公告)号：US07105661B2
公开(公告)日：2006-09-12
申请号：US10731857
申请日：2003-12-09
IPC分类号： C07H265/00
摘要： The invention relates to the use of morpholino-nucleosides of formula: in which R1 represents a nucleic base and R2 represents a group corresponding to one of the following formulae: —(CH2)n—NH2 —(CH2)n—SH —(CH2)n—COOH —(CH2)n—OH —(CH2)n—NH—R3 —(CH2)n—SR3 —(CH2)n—CO—R3 —(CH2)n—OR3 in which n is an interger ranging from 1 to 12 and R3 is a group derived from a label, from a protein, from an enzyme, from a fatty acid or from a peptide, as chain terminators in a process of DNA or RNA sequencing by the Sanger method, or for the labelling of DNA or RNA fragments.
-
5.发明授权公开(公告)号：US06838560B1
公开(公告)日：2005-01-04
申请号：US09914221
申请日：2000-02-21
IPC分类号： G01N33/58 , C07H19/00 , C12N15/09 , C12P19/34 , C12Q1/68 , G01N33/53 , G01N33/566 , C07D265/00
摘要： The invention relates to the use of morpholino-nucleosides of formula: in which R1 represents a nucleic base and R2 represents a group corresponding to one of the following formulae: —(CH2)n—NH2 —(CH2)n—SH —(CH2)n—COOH —(CH2)n—OH —(CH2)n—NH—R3—(CH2)nS—R3 —(CH2)n—CO—R3 —(CH2)n—OR3 in which n is an integer ranging from 1 to 12 and R3 is a group derived from a label, from a protein, from an enzyme, from a fatty acid or from a peptide, as chain terminators in a process of DNA or RNA sequencing by the Sanger method, or for the labelling of DNA or RNA fragments.
-
-
-
-
搜索结果
5 条记录 (耗时 0.025 秒)